Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6958
Lubiprostone Product means a pharmaceutical preparation for human use that contains the compound SPI-0211 as an active ingredient.
Selection Pool Compound means any prostone compound (or analog, prodrug, precursor or metabolite thereof) (i) derived.
IP relates to develop and commercialize AMITIZA, cobiprostone and SPI-017 and any other prostone compounds, other than Rescula, subject to the Companyâ€™s patents.
The patents that are owned and maintained by Licensor are based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The Licensee provides certain development funding to the Licensor.
If the Licensee has not committed specified development efforts to any prostone compound other than AMITIZA, cobiprostone and SPI-017 by the end of a specified period, which ends on the later of June 30, 2011, then the commercial rights to that compound will revert to the Company, subject to a 15-month extension in the case of any compound designated by the Licensee in good faith as planned for development within that extension period. Upon expiration of the 15th anniversary of the first commercial sale of the Licensed products, the Licenses shall be royalty free.
A-11 PROSTAGLANDINS OF THE D SERIES, AND TRANQUILIZERS AND SOPORIFICS CONTAINING THE SAME U.S.A. CIP 403774 1989/9/6 5073569 1991/12/17
A-11 PROSTAGLANDINS OF THE D SERIES, AND TRANQUILIZERS AND SOPORIFICS CONTAINING THE SAME U.S.A. DIV 715151 1991/6/13 5137915 1992/8/11
A-11 PROSTAGLANDINS OF THE D SERIES, AND TRANQUILIZERS AND SOPORIFICS CONTAINING THE SAME U.S.A. CA3 8/310109 1994/9/23 5534547 1996/7/9
A-12 PROSTAGLANDINS E AND ANTI ULCERS CONTAINING SAME U.S.A. DIV2 08/401675 1995/3/10 5886034 1999/3/23
A-12 PROSTAGLANDINS E AND ANTI ULCERS CONTAINING SAME U.S.A. DIV3 09/073253 1998/5/6 6265440 2001/7/24
A-15 FERVESCENCE COMPOSITION U.S.A. CIP 440449 1989/11/22 5001154 1991/3/19
A-17 CATHARTICS U.S.A. CA2 996495 1992/12/30 5317032 1994/5/31
A-22 TRACHEOBRONCHODILATOR U.S.A. CA2 8/77495 1993/6/17 5362751 1994/11/8
Cobiprostone is an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs).
We are conducting preclinical development of SPI-017 for the treatment of peripheral arterial and vascular disease, central nervous system disorders. Initially, we are working on the development of an intravenous formulation of SPI-017 for the treatment of peripheral arterial disease and stroke. We also are developing an oral formulation of SPI-017 for the treatment of Alzheimerâ€™s disease.
IPSCIO Record ID: 26300
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 240606
The patents include Methods and Compositions for Inhibition of Aging, and, Spin-Trapping Pharmaceuticals Compositions and Methods for Use Thereof.